These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23453499)

  • 1. L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: therapeutic options.
    Cacoub P; Terrier B; Saadoun D
    Presse Med; 2013 Apr; 42(4 Pt 2):523-7. PubMed ID: 23453499
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
    Saadoun D; Delluc A; Piette JC; Cacoub P
    Curr Opin Rheumatol; 2008 Jan; 20(1):23-8. PubMed ID: 18281853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of chronic hepatitis C].
    Schaffstein S; Rampini SK; Müllhaupt B
    Praxis (Bern 1994); 2014 Apr; 103(8):423-36. PubMed ID: 24713377
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of hepatitis C-mediated glomerular disease.
    Sandri AM; Elewa U; Poterucha JJ; Fervenza FC
    Nephron Clin Pract; 2011; 119(2):c121-9; discussion c129-30. PubMed ID: 21757949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of monoclonal antibody (rituximab) in the treatment of type II mixed cryoglobulinemia.
    Rego TC; Massumoto CM; Batista RS; Moura LH; Soares LM; Gomes AP
    Braz J Infect Dis; 2007 Feb; 11(1):174-5. PubMed ID: 17625752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acquired hemophilia A in a patient with chronic hepatitis C virus infection receiving treatment with peginterferon α-2a].
    Martínez Pascual C; Antón Ródenas G; Ortiz Sánchez ML; Pons Miñano JA
    Med Clin (Barc); 2013 Sep; 141(5):228-9. PubMed ID: 23473306
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.
    Mazzaro C; Zorat F; Caizzi M; Donada C; Di Gennaro G; Maso LD; Carniello G; Virgolini L; Tirelli U; Pozzato G
    J Hepatol; 2005 May; 42(5):632-8. PubMed ID: 15826710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.
    Saadoun D; Resche Rigon M; Thibault V; Longuet M; Pol S; Blanc F; Pialoux G; Karras A; Bazin-Karra D; Cazorla C; Vittecoq D; Musset L; Decaux O; Ziza JM; Lambotte O; Cacoub P
    Ann Rheum Dis; 2014 May; 73(5):831-7. PubMed ID: 23606708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.
    Saadoun D; Resche Rigon M; Pol S; Thibault V; Blanc F; Pialoux G; Karras A; Bazin-Kara D; Cazorla C; Vittecoq D; Musset L; Peltier J; Decaux O; Ziza JM; Lambotte O; Cacoub P
    J Hepatol; 2015 Jan; 62(1):24-30. PubMed ID: 25135864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies.
    Fabrizi F; Dixit V; Messa P
    J Med Virol; 2013 Jun; 85(6):1019-27. PubMed ID: 23588727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies.
    Garini G; Allegri L; Vaglio A; Buzio C
    Ann Ital Med Int; 2005; 20(2):71-80. PubMed ID: 16052839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
    Emery JS; Kuczynski M; La D; Almarzooqi S; Kowgier M; Shah H; Wong D; Janssen HLA; Feld JJ
    Am J Gastroenterol; 2017 Aug; 112(8):1298-1308. PubMed ID: 28291241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness and safety of antiviral therapy of military personnel suffering from chronic hepatitis C].
    Zhdanov KV; Gusev DA; Kozlov KV; Shishkin MK; Sukachev VS; Shakhmanov DM; Zhabrov SS
    Voen Med Zh; 2015 Apr; 336(4):44-9. PubMed ID: 26454938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
    Landau DA; Rosenzwajg M; Saadoun D; Trébeden-Negre H; Klatzmann D; Cacoub P
    Arthritis Rheum; 2008 Sep; 58(9):2897-907. PubMed ID: 18759287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic hepatitis C: improved cure rates with new approved medications].
    Grammatikos G; Vermehren J; Zeuzem S
    MMW Fortschr Med; 2012 Jun; O 154 Suppl 2():65-9; quiz 70. PubMed ID: 22916428
    [No Abstract]   [Full Text] [Related]  

  • 17. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatitis C virus therapy to date.
    Foster G; Mathurin P
    Antivir Ther; 2008; 13 Suppl 1():3-8. PubMed ID: 18432157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simeprevir for the treatment of chronic hepatitis C.
    You DM; Pockros PJ
    Expert Opin Pharmacother; 2013 Dec; 14(18):2581-9. PubMed ID: 24138198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C.
    Rumi M; Aghemo A; Prati GM
    J Viral Hepat; 2012 Jan; 19 Suppl 1():37-41. PubMed ID: 22233412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.